Hepatocellular carcinoma or HCC is the most commonly observed form of liver cancer and the fourth leading cause of ...

Egypt: Curative liver resection (LR) can be safely carried out in carefully selected elderly patients with hepatocellular ...

Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...

In this cohort study involving noncirrhotic patients with chronic hepatitis B, a new prognostic model based on viral load was ...

Patients with HCC treated with a combination of the immune checkpoint inhibitor atezolizumab and angiogenesis inhibitor ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Foscenvivint is under clinical development by Eisai and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase ...

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in ...

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...